Resource Hub

Featured

DreaMed Secures FDA Clearance for MODI

The first FDA-cleared solution to use glucose-monitoring data to automatically optimize insulin dosing for people with type 2 diabetes, across both basal-only and multiple daily injection regimens.

Read Article

Explore All Resources

Press Releases

DreaMed’s MODI Dose Guidance Solution (DGS) Demonstrates Safety and Improved Control in Clinical Investigation

DreaMed Launches its FDA-Cleared Diabetes Management Platform with a Leading U.S. Children's Hospital

endo.digital Simplifies CGM Utilization: Yale Case Study

Medtronic Secures CE Mark for MiniMed™ 780G Advanced Hybrid Closed Loop System

Case Studies

endo.digital Demonstrates 90% Clinical Agreement with Endocrinologists’ Treatment Decisions

endo.digital Simplifies CGM Utilization: Yale Case Study

endo.digital Helps Billings Clinic Increase CGM Data Review Revenue by 60%

Yale New Haven Health Frees Up 9 Minutes Per Patient Visit With endo.digital’s EMR Integrated Deployment

Research

Insulin Dose Optimization Using an Automated Artificial Intelligence-based Decision Support System in Youths With Type 1 Diabetes

Comprehensive Telehealth Model to Support Diabetes Self-Management

Comparison of Insulin Dose Adjustments Made by Artificial Intelligence-Based Decision Support Systems and by Physicians in People with Type 1 Diabetes Using Multiple Daily Injections Therapy

Adjustment of Insulin Pump Settings in Type 1 Diabetes Management: Advisor Pro Device Compared to Physicians' Recommendations

Media

DreaMed Introduction

endo.digital Interview with Dr. Danielle Benaviv-Meskin

Billings Clinic - Revolutionizing Rural Diabetes Care